Improvement of hypertension and LVH in maintenance hemodialysis patients treated with sustained-release isosorbide mononitrate

Journal of Nephrology

Volumn 24, Issue 2, 2011, Pages 236-245

  Li, Han ^a   Wang, Shi Xiang ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Hypertension; Hypertrophy; Isosorbide mononitrate; Left ventricular hypertrophy; Renal dialysis

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; HEMOGLOBIN; ISOSORBIDE 5 NITRATE; RENIN INHIBITOR;

ACUTE HEART FAILURE; ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART RATE; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; HYPERTENSION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SUSTAINED RELEASE FORMULATION; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT GAIN;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DELAYED-ACTION PREPARATIONS; FEMALE; HEART FAILURE; HEART RATE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INCIDENCE; ISOSORBIDE DINITRATE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS; STROKE VOLUME; TREATMENT OUTCOME; VASODILATOR AGENTS; YOUNG ADULT;

EID: 79953700840     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.5301/JN.2011.6252     Document Type: Article

References (32)

1. Fernandez JM, Carbonell ME, Mazzuchi N, et al. Simultaneous analysis of morbidity and mortality factors in chronic hemodialysis patients. Kidney Int. 1992;41:1029-1034.
2. Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis. Kidney Int. 1992;41:1286-1291.
3. Conion PJ, Walshe JJ, Heinle SK, et al. Predialysis systolic blood pressure correlates strongly with mean 24-hour systolic blood pressure and left ventricular mass in stable hemodialysis patients. J Am Soc Nephrol. 1996;7:2658-2663.
4. Zager PG, Nikolic J, Brown RH, et al. "U" curve association of blood pressure and mortality in hemodialysis patients. Kidney Int. 1998;54:561-569.
5. Port FK, Hulbert-Shearon TE, Wolfe RA, et al. Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis. 1999;33:507-517.
6. Mazzuchi N, Carbonell E, Fernandez-Cean J. Importance of blood pressure control in hemodialysis patient survival. Kidney Int. 2000;58:2147-2154.
7. US Renal Data System. 1999 annual data report. Am J Kidney Dis. 1999;34:557-560.
8. Hou FF. How to improve the outcome of cardiovascular diseases in patients with chronic renal failure. Chin J Integr Med. 2002;41:507-508.
9. London G. Pathophysiology of cardiovascular damage in the early renal population. Nephrol Dial Transplant. 2001;16:3-6.
10. Zoccali C, Mallamaci F, Maas R, et al. Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 2002;62:339-345.
11. Raj DS, Vincent B, Simpson K, et al. Hemodynamic changes during hemodialysis: role of nitric oxide and endothelin. Kidney Int. 2002;61:697-704.
12. Schmidt RJ, Domico J, Samsell LS, et al. Indices of activity of the nitric oxide system in hemodialysis patients. Am J Kidney Dis. 1999;34:228-234.
13. Chamney PW, Krämer M, Rode C, et al. A new technique for establishing dry weight in hemodialysis patients via whole body bioimpedance. Kidney Int. 2002;61:2250-2258.
14. De Simone G, Devereux RB, Roman MJ, et al. Relation of obesity and gender to left ventricular hypertrophy in normotensive and hypertensive adults. Hypertension. 1994;23:600-606.
15. Lu ZY. Acute heart failure. In: Lu ZY, Zhong NS, eds. Internal medicine. 7th ed. Beijing: The People's Medical Publishing House; 2008:179-181.
16. China Pharmacopoeia Commission. The clinical guide to the Chinese pharmacopoeia. Vol. II. Chemical drugs and biological products. Beijing: The People's Medical Publishing House; 2005:636-696.
17. Chen XQ, Jin YY, Tang G. New pharmacology. 15th ed. Beijing: The People's Medical Publishing House; 2003:675.
18. Agarwal R, Nissenson AR, Batlle D, et al. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003;115:291-297.
19. Foley RN, Parfrey PS, Harnett JD, et al. Impact of hypertension on cardiomyopathy, morbidity and mortality in endstage renal disease. Kidney Int. 1996;49:1379-1385.
20. London GM. Left ventricular hypertrophy: why does it happen? Nephrol Dial Transplant. 2003; 18: viii2-viii6.
21. Leypoldt JK, Cheung AK, Delmez JA, et al. Relationship between volume status and blood pressure during chronic hemodialysis. Kidney Int. 2002;61:266-275.
22. Agarwal R. Volume-associated ambulatory blood pressure patterns in hemodialysis patients. Hypertension. 2009;54:241-247.
23. Igarashi Y, Suzuki H, Imafuku T, et al. Hypertension in patients on chronic hemodialysis: the role of the renin-angiotensin system. Jpn Circ J. 1987;51:479-484.
24. Neutel JM. Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy. Curr Med Res Opin. 2010;26:213-222.
25. Zilch O, Vos PF, Oey PL, et al. Sympathetic hyperactivity in haemodialysis patients is reduced by short daily haemodialysis. J Hypertens. 2007;25:1285-1289.
26. Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106:1974-1979.
27. Mallamaci F, Tripepi G, Maas R, et al. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol. 2004;15:435-441.
28. Osanai T, Fujiwara N, Saitoh M, et al. Relationship between salt intake, nitric oxide and asymmetric dimethylarginine and its relevance to patients with end-stage renal disease. Blood Purif. 2002;20:466-468.
29. London G. Pathophysiology of cardiovascular damage in the early renal population. Nephrol Dial Transplant. 2001;16:3-6.
30. Cooke JP. Asymmetrical dimethylarginine: the Uber marker? Circulation. 2004;109:1813-1818.
31. Kielstein JT, Zoccali C. Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis. 2005;46:186-202.
32. Jugdutt BI, Khanm I. Effect of prolonged nitrate therapy on left ventricular remodeling after canine acute myocardial infarction. Circulation. 1994;89:2297-2307.